Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) registry patients who are on novel oral anticoagulants in community practice.
•Age 18 years or older
•Have been diagnosed with acute ischemic stroke and have been treated with dabigatran, rivaroxaban, apixaban, edoxaban within 7 days prior to admission, or
•Have been diagnosed with intracerebral hemorrhage and have been treated with warfarin or one of the novel oral anticoagulants within 7 days prior to admission
•ARAMIS follow-up study: Ability of patient or legally authorized representative to provide informed consent for longitudinal follow-up indicating they understand the purpose and the requirements of the study and are willing to participate.
•Patients who are transferred from another hospital (unless directly transferred from another hospital emergency department (ED) within 24 hours) or discharged to other acute care facility will be excluded.
Duke Clinical Research Institute
- Providence Los Angeles Research Center
- Providence St. Joseph Medical Center (PSJMC)